4.1 Assessing Clinical Situations & Treatment Options

4.1 Assessing Clinical Situations & Treatment Options

Quick Answer: Before recommending or supplying a medicine, run a structured assessment: full medicines and allergy history, relevant conditions (including pregnancy and organ function), red-flag screen, differential for the presentation, then a clear decision to treat, refer, or escalate — guided by AMH options and Australian guidelines, not by habit alone.

Standard 3.1 Patient-centred, culturally responsive approach carries about 20% of the Intern Written Examination. Items under this standard test process: can you gather the right information, recognise danger, choose a safe pathway, and justify treatment options in Australian practice?

Why structured assessment is non-negotiable

Pharmacists make high-stakes decisions with incomplete information every day. A cough may be a cold, ACE-inhibitor cough, heart failure, or pneumonia. A request for “something for pain” may hide an opioid-seeking pattern, a missed red-flag headache, or a simple musculoskeletal strain. Unstructured intuition fails under time pressure; a repeatable framework does not.

In the restricted open-book exam you may use one paper AMH and one paper APF. Assessment questions still require you to know what to look up and how to integrate findings with the patient’s story.

Gathering history — the core dataset

Collect enough information to support a safe decision, without turning every counter conversation into a full admission clerking. At exam level, map history to these domains:

Medicines history technique: Ask open, then specific. “What medicines do you take, including anything from the supermarket or health food shop?” Then probe: blood pressure tablets, blood thinners, inhalers, eye drops, pain relief, sleep aids, herbal products (e.g. St John’s wort, Ginkgo). Confirm doses, timing, and recent changes. For acute presentations, ask what has already been tried and for how long.

Allergy precision matters. “Allergy to penicillin” needs characterisation: childhood rash of unknown type is not the same as anaphylaxis after amoxicillin. Cross-reactivity decisions (e.g. cephalosporins) depend on that detail. Document reaction type whenever possible.

Organ function is not optional for high-risk drugs. Many Intern Written scenarios hinge on renally cleared agents (e.g. metformin, gabapentin, some antibiotics, DOACs in certain contexts) or hepatically metabolised drugs with narrow margins. If eGFR or liver status is unknown and the choice depends on it, that is a signal to obtain information, choose a safer interim option, or refer.

Red flags — stop, refer, or escalate

Red flags convert a “treat” pathway into “refer” or “emergency”. Memorise patterns, not endless lists.

Systemic / emergency red flags (examples):

• Chest pain, severe dyspnoea, signs of anaphylaxis, unexplained collapse
• Meningism, severe sudden headache, focal neurology, first seizure
• Haematemesis, melaena, black stools with anticoagulant or NSAID use
• Suicidal ideation, acute psychosis, severe agitation with safety risk
• Severe dehydration in infants/elderly, inability to keep fluids down

Presentation-specific red flags (common primary-care contexts):

Escalation levels:

1. Self-care / pharmacist treatment — mild, self-limiting, no red flags, suitable S2/S3 or non-drug advice
2. GP / non-urgent medical review — persistent symptoms, diagnostic uncertainty, need for prescription therapy, multimorbidity complexity
3. Urgent care / ED / ambulance — airway, breathing, circulation, severe pain, stroke/ACS/anaphylaxis patterns, inability to protect self

Never delay emergency pathways to “try something from the pharmacy first.”

Differential thinking for common presentations

Intern Written items often present a symptom cluster. Build a short differential, then use history to narrow.

Example — adult with “reflux” symptoms:

• Typical GORD suitable for short-term acid suppression and lifestyle advice
• Cardiac ischaemia mimicking epigastric pain (exertional, radiation, risk factors)
• Medication-related (e.g. calcium channel blockers, bisphosphonate oesophagitis risk with poor technique)
• Alarm features (dysphagia, GI bleeding, weight loss, anaemia) → medical review, not endless OTC PPI cycles

Example — new cough on “blood pressure tablet”:

• ACE-inhibitor cough (dry, tickly, temporally related to start/dose increase)
• Asthma/COPD exacerbation, infection, heart failure, GORD, smoking-related
• Do not automatically stop ACE inhibitors without considering indication (e.g. heart failure, post-MI benefit) — recommend medical review for switch options (often ARB) rather than unsupervised cessation when the drug is disease-modifying

Differential reasoning on the exam is shown by what you ask next and which option you reject, not by listing every disease name.

Treat, refer, or escalate — decision framework

Use a transparent sequence:

1. Is this emergency? → escalate immediately.
2. Is diagnosis clear enough for pharmacist-scope management? If no → refer with safety-netting.
3. Is non-pharmacological care first-line or adjunct? (hydration, wound care, inhaler technique, trigger avoidance).
4. Is a medicine indicated? Check AMH for dose, max duration, contraindications, interactions, pregnancy category/lactation notes as relevant.
5. Is the formulation and regimen feasible for this patient? (see 4.3).
6. What follow-up and safety-net advice closes the loop? Time to review, worsening signs, when to seek care.

Safety-netting language should be specific: “If fever continues beyond 48 hours, breathing worsens, or you cannot keep fluids down, seek medical care today,” not vague “see a doctor if worried.”

Using the AMH for treatment options (exam skill)

Under open-book rules, the AMH is your options and constraints engine. Practice looking up:

• Indications and usual adult/child doses
• Contraindications and precautions (renal, hepatic, elderly, pregnancy)
• Major interactions and combination warnings
• Comparative notes within a class when choosing agents
• Formulation differences that affect onset or suitability

Efficient AMH workflow in a scenario:

1. Identify the therapeutic question (e.g. “acute cystitis in non-pregnant adult woman” vs “analgesia in CKD”).
2. Open the relevant chapter/monograph path you know from practice.
3. Confirm one preferred option and one reason another option is wrong (interaction, organ function, allergy, age, duration).
4. Check counselling essentials that affect efficacy/safety (timing with food, max daily dose, duration limits).

Do not invent doses from memory when the book is available — but do know which tables and monographs to open quickly.

Integrating guidelines with patient goals

Australian practice integrates Therapeutic Guidelines, condition-specific national guidance, and product information. Guidelines answer “what is generally preferred”; patients answer “what is acceptable and achievable.”

Integration habits:

• Prefer first-line options supported by guidelines unless a patient-specific barrier exists (allergy, cost access, prior ADR, organ impairment).
• For infection, respect antimicrobial stewardship: spectrum, duration, and culture/follow-up where relevant.
• For chronic disease, align with targets the patient and prescriber are working toward (BP, HbA1c, symptom control), not isolated numbers without context.
• Reassess when multiple guidelines collide (e.g. NSAID for pain vs cardiovascular/renal risk).

Risk–benefit in multimorbidity and polypharmacy

Multimorbidity is the default in older adults and many chronic-disease cases. Single-disease logic produces cascades: treating each problem adds drugs that cause new problems.

Risk–benefit questions to run every time:

• What is the absolute benefit of this medicine for this patient’s goals (longevity, symptom relief, function)?
• What harms are most likely (falls, hypoglycaemia, bleeding, confusion, constipation, AKI)?
• Is a drug treating an ADR of another drug (prescribing cascade)?
• Can one agent cover two goals (e.g. careful selection in hypertension + proteinuria pathways) without unsafe combinations?
• Is deprescribing or dose reduction the safer “treatment option” today?

Example cascade: amlodipine → ankle oedema → misdiagnosed as heart failure → diuretic → incontinence → anticholinergic → confusion → fall. Recognition of cascades is a hallmark of patient-centred assessment.

Putting it together — worked mini-pathways

Pathway A — Suitable to treat in pharmacy (simplified): Young adult with typical seasonal allergic rhinitis, no red flags, known triggers, requests non-sedating antihistamine. History clear for no interacting sedatives needed; counsel on onset, dry mouth, and when symptoms suggest infection or asthma need review.

Pathway B — Refer (not emergency): Older adult with new dyspepsia, on long-term NSAID for osteoarthritis, mild anaemia recently mentioned by GP but not investigated from pharmacy view. OTC PPI for a few days may mask alarm features; recommend timely GP review, discuss NSAID risk, and avoid repeated blind acid suppression without assessment.

Pathway C — Escalate: Patient collecting antibiotics develops facial swelling and difficulty breathing after first dose of amoxicillin — anaphylaxis pathway: emergency services, adrenaline per emergency protocol, do not delay for “mild allergy” assumptions.

Documentation and communication

Even when the exam is MCQ, think like a documenter:

• What history elements were critical?
• What option was chosen and why alternatives were rejected?
• What referral urgency and safety-net were given?

Clear reasoning is what Standard 3.1 rewards: patient-centred process first, product selection second.